IBD-Associated Arthritis News

The common consensus for some time has been that the prevalence of autoimmunity and autoimmune diseases has been on the rise.

Fatigue in patients with inflammatory rheumatic and musculoskeletal diseases should be addressed with tailored physical activity, psychoeducational interventions or possibly immunomodulatory treatment, according to EULAR recommendations.

Poverty and chronic inflammation together may have a “synergistic” impact leading to higher all-cause mortality, including a 127% increased heart disease mortality risk and a 196% higher risk for cancer mortality, according to data.

The first 10 drugs eligible for price negotiation through Medicare includes etanercept and ustekinumab, biologic therapies commonly used to treat patients with rheumatic diseases, the Biden administration announced.

The emergence of biosimilar TNF inhibitors in Poland led to reduced prices and expenditures, but little improvements in treatment availability, according to data published in Annals of the Rheumatic Diseases.

Patients with immune checkpoint inhibitor-associated inflammatory arthritis who receive a biologic DMARD demonstrate quicker arthritis control, but also experience faster cancer progression, vs. methotrexate, according to data.

CHICAGO — In patients with inflammatory bowel disease, a “strong and consistent three-way interaction” was identified between HLA-B27, male sex and the development of sacroiliitis, according to data presented at Digestive Disease Week.

Properly managing cardiovascular disease in patients with immune-mediated inflammatory diseases requires following guidelines and inter-specialty collaboration, according to a speaker at the Biologic Therapies Summit.

SCOTTSDALE, Ariz. — Although TNF inhibitors can work “across the spectrum” in spondyloarthritis, they are “not always” the standard of care, according to a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium.